These results claim that Acetylon's selective HDAC1/2 inhibitor substances are capable of inducing HbF expression with a pharmacokinetic profile suitable for clinical advancement for the potential treatment of SCD and bT. The analysis results are being shown by Jeffrey Shearstone, Ph.D., of Acetylon during an ASH poster session today in a poster titled, ‘Induction of Human Fetal Hemoglobin Expression by Selective Inhibitors of Histone Deacetylase 1 and 2 .’.. Acetylon announces outcomes from selective HDAC 1/2 inhibitor preclinical research on SCD and bT Acetylon Pharmaceuticals Inc., a head in targeted epigenetic medication development and discovery for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase 1/2 inhibitor for the treating sickle cell disease and beta-thalassemia at the 54th Annual Achieving of the American Culture of Hematology , taking place in Atlanta, Georgia.Certified from medwireNews with authorization from Springer Health care Ltd. All privileges reserved. Neither of these ongoing celebrations endorse or recommend any commercial products, services, or equipment.. A.O. Fox Hospital deploys Phytel’s Web-based human population health insurance and patient engagement platform A.O. Fox Medical center, a not-for-profit community hospital in Oneonta, N.Y. And affiliate of the Bassett Healthcare Network, provides deployed Phytel's in depth, Web-based population health and patient engagement platform.